Resistance of MDR-TB and XDR-TB strains to SQ109 and the relationship with Beijing genotypes

doi:10.3969/j.issn.1000-6621.2018.05.013

Abstract

Abstract:

Objective To evaluate the susceptibility of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains against SQ109, an analogue of ethambutol (EMB, a new anti-TB drug), and to provide evidence for the clinical application of SQ109.Methods Two hundred and twenty three strains including 109 MDR-TB and 114 XDR-TB were collected from the patients seeking health care in Beijing chest hospital from July 2014 to December 2016. The minimum inhibitory concentrations (MIC) of MTB isolates against SQ109 were detected by broth dilution micro-plate alamar blue assay. The epidemiological cutoff (ECOFF) value was determined on the basis of distribution of MIC values. RD207 gene was used to distinguish Beijing genotype and non-Beijing genotype. Difference in SQ109 resistance rates between groups was compared. According to the results of clinical drug sensitivity test, the EMB resistant strains were isolated, and SQ109 resistance rate was compared between EMB resistant and sensitive strains.Results The ECOFF value was determined to be 1.000 mg/L according to the frequency distribution of MIC against SQ109. The resistance rate was 4.4% (5/114) and 0.0% among XDR-TB and MDR-TB isolates, respectively. There was no statistical difference in SQ109-resisitant rate between MDR-TB and XDR-TB (Fisher exact probabilities, P>0.05). Eight isolates out of 109 MDR strains and 10 isolates out of 114 XDR strains were classified as non-Beijing genotype. The resistant rate of the Beijing geno-type strain was 2.4% (5/205), while no non-Beijing genotype strain harbored SQ109 resistance. Statistical analysis revealed that no significant difference was observed in SQ109 resistance rate between Beijing and non-Beijing group (Fisher exact probabilities, P>0.05). Of the 223 strains, there were 138 EMB sensitive strains and 85 EMB resistant strains. Among EMB sensitive strains, only one was resistant strain against SQ109, and the resistance rate was 0.7% (1/138). Among the EMB resistant strains, 4 strains were resistant to SQ109, and the resistance rate was 4.7% (4/85). The difference in SQ109 resistance rate between EMB sensitive and resistant strains was not statistically significant (Fisher exact probabilities, P>0.05).Conclusion SQ109 exhibits favorable efficacy against MDR- and XDR-TB isolates in vitro. In addition, there is no statistical correlation between SQ109 resistance and Beijing genotype or between EMB resistance and SQ109 resistance.

Key words: Mycobacterium tuberculosis, Drug resistance, multiple, bacterial, Genotype, Causality, SQ109

Wen-zhu DONG,Zheng WANG,Shu-an WEN,Ting-ting ZHANG,Feng-min HUO,Ling-ling DONG,Yun-xu LI,Li-ping ZHAO,Hai-rong HUANG,Fei GAO,Yu PANG. Resistance of MDR-TB and XDR-TB strains to SQ109 and the relationship with Beijing genotypes[J]. Chinese Journal of Antituberculosis, 2018, 40(5): 506-511. doi: 10.3969/j.issn.1000-6621.2018.05.013

Figures/Tables 1

References 11

[1]	Chen P, Gearhart J, Protopopova M , et al. Synergistic intera-ctions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother, 2006,58(2):332-337. doi: 10.1093/jac/dkl227 URL
[2]	Pang Y, Zheng H, Tan Y , et al. In vitro activity of bedaquiline against nontuberculous Mycobacteria in China. Antimicrob Agents Chemother, 2017, 61(5). pii:e02627-16. doi: 10.1128/AAC.02627-16 URL pmid: 5404590
[3]	Sacksteder KA, Protopopova M , Barry CE 3rd, et al. Disco-very and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol, 2012,7(7):823-837. doi: 10.2217/fmb.12.56 URL pmid: 22827305
[4]	中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2012年)(第二部分结核病临床治疗). 中国防痨杂志, 2013,35(7):488-510.
[5]	杨健, 逄宇, 赵雁林 , 等. 耐多药结核分枝杆菌对环丝氨酸、对氨基水杨酸的耐药性及其与基因型关系分析. 中国防痨杂志, 2015,37(2):122-127. doi: 10.3969/j.issn.1000-6621.2015.02.002 URL
[6]	Pang Y, Zong Z, Huo F , et al. In vitro drug susceptibility of bedaquiline,delamanid,linezolid,clofazimine,moxifloxacin,gatifloxacin against extensively drug-resistant tuberculosis in Beijing,China. Antimicrob Agents Chemother, 2017, 61(10). pii:e00900-17.
[7]	de Knegt GJ, van der Meijden A, de Vogel CP , et al. Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109. Int J Antimicrob Agents, 2017,49(3):302-307. doi: 10.1016/j.ijantimicag.2016.11.027 URL
[8]	Jia L, Tomaszewski JE, Hanrahan C , et al. Pharmacodyna-mics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol, 2005,144(1):80-87.
[9]	Jia L, Noker PE, Coward L , et al. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol, 2006,147(5):476-485. doi: 10.1038/sj.bjp.0706650 URL pmid: 16432511
[10]	Bogatcheva E, Hanrahan C, Nikonenko B , et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg Med Chem Lett, 2011,21(18):5353-5357. doi: 10.1016/j.bmcl.2011.07.015 URL pmid: 21807506
[11]	王胜芬, 赵雁林, 黄海荣 , 等. 结核分枝杆菌北京基因型菌株与耐药表型的关系. 中国医学科学院学报, 2009,31(4):427-431. doi: 10.3881/j.issn.1000-503X.2009.04.009 URL

[1]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[2]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[3]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[4]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[5]	Huang Misun, Wu Yaning, Li Guilian, Liu Haican. Research advances of Mycobacterium tuberculosis enrichment technology [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373.
[6]	Yang Ziyi, Chen Suting. Research progress on bedaquiline resistance and drug resistance diagnosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 374-379.
[7]	Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163.
[8]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[9]	Xu Zian, Pu Feifei, Feng Jing, Xia Ping. Research progress of high-throughput sequencing technology in the diagnosis and treatment of osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 224-230.
[10]	Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111.
[11]	Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60.
[12]	Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65.
[13]	Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang. Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76.
[14]	Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong. Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055.
[15]	Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068.